Concepedia

Nora Zizlsperger

NZ

Statistics

Publications

10

Citations

1.6K

H-Index

10

Active since

2004

Affiliations

Infinity Pharmaceuticals (United States)(Current)

University of California, Los Angeles

Massachusetts Institute of Technology

Massachusetts General Hospital

The University of Texas MD Anderson Cancer Center

Nora Zizlsperger is an author at Infinity Pharmaceuticals (United States) specializing in medicine, pharmacology, and cancer immunotherapy.

ORCID

Publications per year

2004–2024

10

Publications

10

Control of Pancreas and Liver Gene Expression by HNF Transcription Factors

Duncan T. Odom, Nora Zizlsperger, D. Benjamin Gordon et al. · Science · 2004 · 1.3K citations · Full text

, , +17

Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial

David S. Hong, Michael A. Postow, Bartosz Chmielowski et al. · Clinical Cancer Research · 2023 · 78 citations · Full text

, , +17

Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment

Brenda O’Connell, Charley J. Hubbard, Nora Zizlsperger et al. · Journal for ImmunoTherapy of Cancer · 2024 · 60 citations · Full text

, , +17

Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity

Uğur Eskiocak, Wilson Guzman, Benjamin Wolf et al. · JCI Insight · 2020 · 47 citations · Full text

, , +17

Abstract P5-16-02: Updated efficacy, safety and translational data from MARIO-3, a phase II open-label study evaluating a novel triplet combination of eganelisib (IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC)

Soliman Hatem, Jeffrey B. Hargis, Anthony Elias et al. · Cancer Research · 2022 · 24 citations

, , +17

1–5 of 10